CNS Pharmaceuticals Inc
NASDAQ:CNSP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CNS Pharmaceuticals Inc
NASDAQ:CNSP
|
US |
Intrinsic Value
The intrinsic value of CNS Pharmaceuticals Inc (CNSP) under the Base Case is 5.66 USD per share.
Compared with the current market price of 5 USD, the stock appears
Undervalued by 12% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What CNS Pharmaceuticals Does
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier.
- Headquarters
- United States of America US
- Employees
- 5
- IPO date
- Nov 8, 2019
Revenue & Expenses Breakdown
CNS Pharmaceuticals Inc
Earnings Waterfall
CNS Pharmaceuticals Inc
The intrinsic value for CNS Pharmaceuticals Inc (CNSP) under the Base Case is 5.66 USD.
Compared with the current market price of 5 USD, the stock appears Undervalued by 12% .